ValiRx wins €1.6m grant to develop genetics-based cancer treatment

29 August 2013

Cancer therapeutics company ValiRx plc has announced that it and consortium member Pharmatest Services have been awarded a €1.6 million Eurostars grant to progress the pre-clinical studies of its novel product VAL101.

VAL101 is the company’s lead candidate deriving from the GeneICE platform for controlling 'rebellious' genes. The funds will also go to building associated cancer models and developing further GeneICE compounds directed at known cancer targets.

This award follows a previous Eurostars grant of €1.4 million, the programme for which was completed earlier this year and was accepted by both the UK Technology Strategy Board (TSB) and the Eurostars Team.

In July this year the company reported that VAL101 was progressing from the the final preclinical proof of concept stage with pharmacokinetics and pharmacodynamics and preliminary toxicology studies underway at the University of Heidelberg, Germany.

The company's leading anti-cancer therapeutic product, VAL201, is going through clinical trials in cancer patients. Results of the trials are expected by the end of 2013.

ValiRx Chief Executive Dr Satu Vainikka said, “I am delighted to see and grateful for continued support from the Eurostars programme. Their grant will substantially help progress our work on VAL101 and GeneICE, which will in turn we believe, build value”.


To top